Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin
Ben Derman, Asst Professor at University of Chicago, posted on X:
“One recommendation I make over and over is to use a prophylactic DOAC instead of aspirin in newly diagnosed myeloma. Just choose a DOAC [they are getting much more affordable!]!
Risk scores lack validation for choosing VTE ppx.
The BENEFIT trial shows 6-month incidence of VTE was 0.8% in patients receiving ppx DOAC vs 5.6% with ppx heparin, and 9.8% in patients receiving aspirin.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors:Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read full article here.
Stay informed with Hemostasis Today.
-
Apr 23, 2026, 16:26Ifeanyichukwu Ifechidere: The Framework for Mastering Coagulation Fundamentals
-
Apr 23, 2026, 16:12Fayad Al-Haimus։ HI-PEITHO Shows Reduced PE Complications Without Increased Bleeding
-
Apr 23, 2026, 16:04Hamid Yousaif Qureshi: Japanese Scientists Develop Artificial Blood
-
Apr 23, 2026, 15:5810 Treating Fairly Research Awards – ASH
-
Apr 23, 2026, 15:51Abeer Alanazi: Secondary Stroke Prevention in Atrial Fibrillation
-
Apr 23, 2026, 15:46Brian O Mahony: What Causes the Battle Bettle Between AAV and the Liver?
-
Apr 23, 2026, 15:45Toong Youttananukorn: Excited to Share Our Poster at WFH 2026
-
Apr 23, 2026, 15:42Flora Peyvandi: Management of Antithrombotic Treatment in Atrial Fibrillation
-
Apr 23, 2026, 15:38William Aird: Do We Really Need MCH?